Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • OUTLOOK

Why rare genetic diseases are a logical focus for RNA therapies

When two pharmaceutical companies turned their attention to a rare condition, they came up with different strategies for targeting RNA. Now, RNA therapies for other hereditary conditions are within the sights of the industry.
  1. Liam Drew

    1. Liam Drew is a freelance writer based in London.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Ellie Darby-Prangnell has a genetic condition called spinal muscular atrophy. Credit: Marcus Hessenberg/Barcroft Images/Barcroft Media via Getty

In 2018, US and European regulators approved two RNA-targeted drugs for the rare genetic disease hereditary transthyretin (hATTR) amyloidosis, offering hope to around 50,000 people with the condition worldwide.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 574, S16-S18 (2019)

doi: https://doi.org/10.1038/d41586-019-03075-5

This article is part of Nature Outlook: RNA therapy, an editorially independent supplement produced with the financial support of third parties. About this content.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links